{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'concentration and ATA data from this study may be combined with data from other', 'studies and analyzed using population pharmacokinetic methodologies.', 'The relationship between pharmacokinetics (e.g., exposure) and clinical trial findings', 'including, but not limited to demographics, efficacy, and/or safety measures may also be', 'explored. Additional analyses will be performed if useful. Results of the population', 'pharmacokinetic and exposure-response analyses will be provided in a separate report.', '8.2', 'Safety Analyses', 'Safety endpoints will be summarized using data from the Safety set. Safety analyses will', 'involve examination of the incidence, severity, and type of treatment-emergen adverse', 'events (TEAEs) reported, changes in vital signs and laboratory test results from baseline', '(the assessment prior to first dose) to specified time points throughout the study, and', 'concomitant medications used. NCI CTCAE version 4.0 will be used in the grading of', 'adverse events and laboratory abnormalities that are reported as adverse events.', '8.2.1', 'Treatment-Emergent Adverse Events (TEAEs)', 'TEAEs reported during the study will be coded using a MedDRA 16 dictionary. Incidence', 'of TEAEs will be summarized by treatment arm and the following:', 'System organ class and preferred term', 'System organ class, preferred term, and severity', 'These summaries will be presented for the following subsets:', 'Serious TEAEs', 'All TEAEs', 'Drug-related TEAEs', 'For tables reporting AEs by severity, if a subject has multiple occurrences of an AE with', 'the same organ class and preferred term, the most severe event will be presented.', '100']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.2.2', 'Clinical Laboratory Evaluation', 'Laboratory parameters will be summarized by treatment arm at each visit. Each summary', 'will include the values of the laboratory parameters and changes from baseline. Shift', 'tables from baseline will be presented for laboratory values in the chemistry and', 'hematology panels. Parameters will be classified according to the laboratory reference', 'normal ranges. A listing will be provided for out-of-normal range as well as clinically', 'significant abnormal lab values.', '8.2.3', 'Vital Signs', 'Vital signs including pulse, blood pressure, temperature, and body weight will be', 'summarized by treatment arm and time point. For each assessment of vital signs, change', 'from baseline will be summarized by treatment arm.', '8.2.4', 'ECOG Performance Status', 'ECOG performance status will be summarized for each visit by treatment arm. Shifts', 'from baseline to the best and worst post-baseline score may be tabulated.', '8.2.5', 'Electrocardiogram', 'ECG status will be summarized for each scheduled visit by treatment arm. Shifts from', 'baseline may be tabulated.', '8.2.6', 'Concomitant Medications', 'Concomitant medications will be classified according to the anatomical therapeutic', 'chemical (ATC) codes in the World Health Organization Drug (WHODRUG) dictionary.', 'The incidence rate of each coded concomitant medication will be tabulated by treatment', 'arm. The table will be sorted by the incidence use of the entire sample.', '8.3', 'Type I Error Adjustment Procedure for Multiple Testing', 'To meet global regulatory requirements, a multiple testing strategy will be implemented to', 'control the family-wise type I error (alpha) to one-sided 0.025 level for comparisons of', '101']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival', '(PFS) per CRAC in DLL3 high set, overall survival (OS) in DLL3 high set, PFS per CRAC in', 'randomized set, OS in randomized set, and physical functioning scale score (EORTO', 'QLQ-C30) in randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in Hoi are Hola and Holb.', 'Ho1a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'DLL3 high set.', 'Ho1b: Rovalpituzumab tesirine arm is not superior to placebo arm in os in DLL3 high set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in OS in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning', 'scale score (EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {H01a, Holb, H02, H03, and H04} in', 'order. To maintain the family-wise type I error for the study, the null hypotheses in H01', '(Ho1a and H01b) will be first tested with an alpha-split approach. The one-sided alpha of', '0.25% and 2.25% will be assigned for PFS and os hypothesis in H01, respectively. Out of', 'one-sided alpha of 2.25% allocated to OS hypothesis (Hoib), the one-sided alpha of 10-6', 'will be spent for the early look at the OS data for futility analysis. If the hypothesis for', 'PFS in H01 (Ho1a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in Hoi (Hoib). Hence, the hypothesis for OS in H01 (Hoib) will be tested either', 'at a one-sided 2.4999% or one-sided 2.2499% level of significance depending on the PFS', 'hypothesis in Ho1a is rejected or not.', '102']\n\n###\n\n", "completion": "END"}